Presentation is loading. Please wait.

Presentation is loading. Please wait.

Preoperative Concurrent Chemoradiotherapy of S-1/Cisplatin for Stage III Non-Small Cell Lung Cancer  Masafumi Yamaguchi, MD, PhD, Gouji Toyokawa, MD,

Published byArnold Mosley Modified over 5 years ago

Similar presentations

Presentation on theme: "Preoperative Concurrent Chemoradiotherapy of S-1/Cisplatin for Stage III Non-Small Cell Lung Cancer  Masafumi Yamaguchi, MD, PhD, Gouji Toyokawa, MD,"— Presentation transcript:

1 Preoperative Concurrent Chemoradiotherapy of S-1/Cisplatin for Stage III Non-Small Cell Lung Cancer 
Masafumi Yamaguchi, MD, PhD, Gouji Toyokawa, MD, PhD, Taro Ohba, MD, PhD, Tomonari Sasaki, MD, PhD, Takuro Kometani, MD, PhD, Motoharu Hamatake, MD, PhD, Fumihiko Hirai, MD, PhD, Kenichi Taguchi, MD, PhD, Takeharu Yamanaka, PhD, Takashi Seto, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Kenji Sugio, MD, PhD, Yukito Ichinose, MD, PhD  The Annals of Thoracic Surgery  Volume 96, Issue 5, Pages (November 2013) DOI: /j.athoracsur Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 The survival curve of all 39 resected patients. (A) Disease-free survival and (B) overall survival. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 The prognosis of patients stratified by the pathologic response of the resected specimen. Solid line represents patients with complete pathologic response (CPR), while dashed line represents the patients with partial pathologic response (PPR). (A) Disease-free survival; (B) overall survival. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Preoperative Concurrent Chemoradiotherapy of S-1/Cisplatin for Stage III Non-Small Cell Lung Cancer  Masafumi Yamaguchi, MD, PhD, Gouji Toyokawa, MD,"

Similar presentations

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Thomas J. Birdas, MD, Richard P. M

Thomas J. Birdas, MD, Richard P. M
Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection  Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.

Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection  Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient with Disseminated Intravascular Coagulation  Gouji Toyokawa, MD, PhD, Mitsuhiro.

Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient with Disseminated Intravascular Coagulation  Gouji Toyokawa, MD, PhD, Mitsuhiro.
Long Interspersed Nucleotide Element 1 Hypomethylation Is Associated With Poor Prognosis of Lung Adenocarcinoma  Koei Ikeda, MD, PhD, Kenji Shiraishi,

Long Interspersed Nucleotide Element 1 Hypomethylation Is Associated With Poor Prognosis of Lung Adenocarcinoma  Koei Ikeda, MD, PhD, Kenji Shiraishi,
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,
Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non– small-cell Lung Cancer Exhibiting Resistance to Ceritinib  Gouji Toyokawa,

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non– small-cell Lung Cancer Exhibiting Resistance to Ceritinib  Gouji Toyokawa,
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.
Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220  Kemp H. Kernstine, MD, PhD, James.

Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220  Kemp H. Kernstine, MD, PhD, James.
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Similar presentations

Ads by Google